All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the advantages of mechanism-based therapies to prevent AML relapse?
Bookmark this article
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, What are the advantages of mechanism-based therapies to prevent AML relapse?
What are the advantages of mechanism-based therapies to prevent AML relapse?
In this video, DiNardo provides an overview of mechanism-based therapies for the prevention of relapse in patients with acute myeloid leukemia (AML). She focuses on the incorporation of genomic information in treatment regimen decisions to optimize response for different patient subgroups.
More about...
Your opinion matters
1 vote - 3 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox